Filippatos TD - Search Results

1

Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association?

Makris A, Barkas F, Sfikakis PP, Liberopoulos E, Filippatos TD, Ray KK, Agouridis AP. Makris A, et al. Among authors: filippatos td. Atheroscler Plus. 2023 Sep 9;54:1-6. doi: 10.1016/j.athplu.2023.09.001. eCollection 2023 Dec. Atheroscler Plus. 2023. PMID: 37720252 Free PMC article. Review.

2

Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study.

Kiortsis DN, Tsouli S, Filippatos TD, Konitsiotis S, Elisaf MS. Kiortsis DN, et al. Among authors: filippatos td. Nutr Metab Cardiovasc Dis. 2008 Mar;18(3):207-10. doi: 10.1016/j.numecd.2006.10.003. Epub 2007 Jun 13. Nutr Metab Cardiovasc Dis. 2008. PMID: 17570651 Clinical Trial.

3

Increased plasma visfatin levels in subjects with the metabolic syndrome.

Filippatos TD, Derdemezis CS, Gazi IF, Lagos K, Kiortsis DN, Tselepis AD, Elisaf MS. Filippatos TD, et al. Eur J Clin Invest. 2008 Jan;38(1):71-2. doi: 10.1111/j.1365-2362.2007.01904.x. Eur J Clin Invest. 2008. PMID: 18173555 No abstract available.

4

Statins and heart failure.

Filippatos TD, Mikhailidis DP. Filippatos TD, et al. Angiology. 2008 Apr-May;59(2 Suppl):58S-61S. doi: 10.1177/0003319708319643. Epub 2008 May 28. Angiology. 2008. PMID: 18508847 Review.

5

Obesity and arterial compliance alterations.

Seifalian AM, Filippatos TD, Joshi J, Mikhailidis DP. Seifalian AM, et al. Among authors: filippatos td. Curr Vasc Pharmacol. 2010 Mar;8(2):155-68. doi: 10.2174/157016110790886956. Curr Vasc Pharmacol. 2010. PMID: 20180777 Review.

6

A review of the metabolic effects of sibutramine.

Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Filippatos TD, et al. Curr Med Res Opin. 2005 Mar;21(3):457-68. doi: 10.1185/030079905X38132. Curr Med Res Opin. 2005. PMID: 15811215 Review.

7

Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study.

Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mikhailidis DP, Elisaf MS. Filippatos TD, et al. Curr Med Res Opin. 2005 Dec;21(12):1997-2006. doi: 10.1185/030079905x75078. Curr Med Res Opin. 2005. PMID: 16368051 Clinical Trial.

8

The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome.

Filippatos TD, Gazi IF, Liberopoulos EN, Athyros VG, Elisaf MS, Tselepis AD, Kiortsis DN. Filippatos TD, et al. Atherosclerosis. 2007 Aug;193(2):428-37. doi: 10.1016/j.atherosclerosis.2006.07.010. Epub 2006 Sep 5. Atherosclerosis. 2007. PMID: 16911813 Clinical Trial.

9

The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol.

Gazi IF, Filippatos TD, Tsimihodimos V, Saougos VG, Liberopoulos EN, Mikhailidis DP, Tselepis AD, Elisaf M. Gazi IF, et al. Among authors: filippatos td. Lipids. 2006 Jul;41(7):647-54. doi: 10.1007/s11745-006-5015-8. Lipids. 2006. PMID: 17069348

10

Statin-associated adverse effects beyond muscle and liver toxicity.

Kiortsis DN, Filippatos TD, Mikhailidis DP, Elisaf MS, Liberopoulos EN. Kiortsis DN, et al. Among authors: filippatos td. Atherosclerosis. 2007 Nov;195(1):7-16. doi: 10.1016/j.atherosclerosis.2006.10.001. Epub 2006 Nov 13. Atherosclerosis. 2007. PMID: 17094994 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

143 results

Search Page